Completed NA INTERVENTIONAL 1-arm NCT04699487

Efficacy and Safety of CareMin650 for Prevention of Oral Mucositis in HNC Patients Starting Radiotherapy (PrOMiSE)

Efficacy and Safety of CareMin650 Used for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer Starting Radiotherapy: the PrOMiSE Study

Sponsor: Monitoring Force Group

Conditions Head and Neck Cancer Oral Mucositis (Ulcerative) Due to Radiation Radiation Therapy Complication

Interventions Photobiomodulation

Updated 4 times since 2021 Last updated: Oct 6, 2022 Started: May 10, 2021 Primary completion: Mar 31, 2022 Completion: Jun 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04699487, this NA trial focuses on Head and Neck Cancer and Oral Mucositis (Ulcerative) Due to Radiation and remains completed. Sponsored by Monitoring Force Group, it has been updated 4 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Nov 2022 — Jul 2024 [monthly]

Completed NA

Status: Not Yet Recruiting → Completed
Feb 2021 — Nov 2022 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Monitoring Force Group
NeoMedLight

Data source: NeoMedLight

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aachen, Germany